FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

BIGHAM MICHAEL 		2. Issuer Name and Ticker or Trading Symbol

Paratek Pharmaceuticals, Inc. [ PRTK ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Chairman and CEO
(Last)          (First)          (Middle)

C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR 		3. Date of Earliest Transaction (MM/DD/YYYY)

7/19/2017
(Street)

BOSTON, MA 02116
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   7/19/2017     M    23255   (1) A $4.30   127680   D  
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (2) $4.30   7/19/2017     M         23255      (3) (4) 6/28/2024   Common Stock   23255   $0   121838   D  
 

Explanation of Responses:
(1)  Shares of common stock acquired from the exercise of a stock option.
(2)  The Issuer entered into an Agreement and Plan of Merger and Reorganization, dated as of June 30, 2014 (the "Merger Agreement"), by and among the Issuer, Tigris Merger Sub, Inc., Tigris Acquisition Sub, LLC and a Delaware corporation then known as Paratek Pharmaceuticals, Inc. ("Old Paratek").
(3)  On June 29, 2014, the Reporting Person was granted an option to purchase 2,149,529 shares of the common stock of Old Paratek under Old Paratek's 2014 Equity Incentive Plan at a per share exercise of price of $0.29 per share. Pursuant to the Merger Agreement, this option was converted into an option to purchase 145,093 shares of the Issuer's common stock at a per share exercise price of $4.30 upon closing of the merger. The option was previously reported on Form 4 filed on November 3, 2014.
(4)  This stock option originally vested monthly over four years measured from the vesting commencement date of January 1, 2015, subject generally to the Reporting Person's continued employment with the Issuer. On October 9, 2015, this stock option was amended to conform the award's vesting schedule to other new hire grants. Following the amendment, 25% of the award would vest on January 1, 2016 with the remaining 75% of the award to vest in a series of thirty-six successive equal monthly installments measured from January 1, 2016, subject generally to the Reporting Person's continued employment with the Issuer.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
BIGHAM MICHAEL
C/O PARATEK PHARMACEUTICALS, INC.
75 PARK PLAZA, 4TH FLOOR
BOSTON, MA 02116 		X
Chairman and CEO

Signatures
/s/ William M. Haskel, Attorney-in-Fact for Michael Bigham 7/21/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Paratek Pharmaceuticals Charts.
Paratek Pharmaceuticals (NASDAQ:PRTK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Paratek Pharmaceuticals Charts.